Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC280 in Chinese Advanced NSCLC Patients
NCT03240393Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jul 2018
- Primary completion
- Oct 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
A Phase 2 trial of capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Planned start Jul 2018; status: withdrawn.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03240393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240393.